文献速递血液净化与透析急性肾损伤

FXI/XIa抑制剂在血液透析终末期肾病患者中的安全性与疗效系统评价

A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis.
PubMed 文献 · Kidney Int Rep · 2024-10-15

该系统评价纳入5项2期随机对照试验(共1270例血液透析的终末期肾病患者),比较FXI/XIa抑制剂与安慰剂。4项研究纳入荟萃分析,结果显示FXI/XIa抑制剂与临床相关出血(OR 0.80,95%CI 0.47-1.35)、大出血(OR 0.51,95%CI 0.21-1.28)风险无显著增加相关,血栓栓塞事件和全因死亡OR分别为0.66和0.46,但置信区间宽,需3期试验验证。

要点

  • FXI/XIa抑制剂在血液透析ESKD患者中未显示显著增加出血风险
  • 血栓栓塞事件和全因死亡OR分别为0.66和0.46,但置信区间宽
  • 现有证据来自2期试验,疗效和死亡率关联需3期试验确认

核心结论

  • 当前证据未显示FXI/XIa抑制剂在血液透析ESKD患者中较安慰剂显著增加出血风险。
  • 其疗效及与全因死亡的关联需足够样本量的3期随机对照试验进一步研究。

研究设计与样本

  • 系统检索Embase、MEDLINE和ClinicalTrials.gov,纳入评估FXI/XIa抑制剂在血液透析ESKD患者中的随机对照试验。
  • 共纳入5项2期研究(1270例参与者),干预药物包括gruticibart、IONIS-FXIRx、osocimab或fesomersen,对照为安慰剂。
  • 4项 fully published 研究纳入荟萃分析,采用随机效应模型计算OR和95%CI。

主要发现

  • 临床相关出血的OR为0.80(95%CI 0.47-1.35)。
  • 大出血的OR为0.51(95%CI 0.21-1.28)。
  • 临床相关非大出血的OR为0.90(95%CI 0.49-1.68)。
  • 血栓栓塞事件的OR为0.66(95%CI 0.28-1.56)。
  • 全因死亡的OR为0.46(95%CI 0.15-1.40)。

临床怎么用

  • 现有证据不支持FXI/XIa抑制剂在血液透析ESKD患者中显著增加出血风险,但疗效未确证。
  • 临床使用仍需谨慎,等待3期随机对照试验结果。

局限性

  • 纳入研究均为2期试验,样本量有限,置信区间宽。
  • 仅4项研究纳入荟萃分析,证据强度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Factor XI/XIa (FXI/XIa) has emerged as a potential target for antithrombotic therapy, driven by preclinical evidence showing the role of FXI/XIa inhibition for preventing thrombosis without impeding hemostasis. This is particularly promising for patients at high risk of both thromboembolic events and bleeding, such as patients with end-stage kidney disease (ESKD) on hemodialysis (HD). METHODS: We systematically searched Embase, MEDLINE, and ClinicalTrials.gov for randomized controlled trials evaluating FXI/XIa inhibitors in patients with ESKD on HD, without restricting inclusion to specific comparators or indications. Interventional treatment arms were pooled, and study results were synthesized by fitting random-effects models, calculating odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Five phases 2 studies encompassing 1270 participants were identified, investigating gruticibart, IONIS-FXIRx, osocimab, or fesomersen in the general HD population and using placebo as a comparator. Four studies were fully published and included in the meta-analysis. Use of FXI/XIa inhibitors was associated with an OR of 0.80 (95% CI = 0.47-1.35) for clinically relevant bleeding, 0.51 (95% CI = 0.21-1.28) for major bleeding, and 0.90 (95% CI = 0.49-1.68) for clinically relevant nonmajor bleeding. The ORs for thromboembolic events and all-cause mortality were 0.66 (95% CI = 0.28-1.56) and 0.46 (95% CI = 0.15-1.40), respectively. CONCLUSION: Currently available evidence does not indicate a significantly increased bleeding risk of FXI/XIa inhibitors in patients with ESKD on HD compared to placebo. Their efficacy and their association with all-cause mortality need to be investigated in sufficiently powered, randomized controlled phase 3 trials.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Steiner D, Kraemmer D, Nopp S, et al. A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis. Kidney Int Rep. 2024. PMID: 39810768. doi:10.1016/j.ekir.2024.10.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。